Literature DB >> 19479485

Pharmacology and pharmacogenetics of chemotherapeutic agents.

Shaheenah Dawood1, Brian Leyland-Jones.   

Abstract

The last decade the field of oncology has seen the introduction of several efficacious chemotherapeutic agents. However the benefits achieved have been modest at best. The choice of chemotherapeutic agent is often empirical and geared to fit the average patient with the result that approximately 40% of patients may be receiving the wrong drug. With greater understanding of the mechanisms behind the heterogeneity observed across patient populations, both in terms of efficacy and toxicity of a variety of therapeutic agents, research has now focused on individualizing treatment strategies by incorporating a combination of physiological variables, genetic characteristics and environmental factors together with the traditional tumor characteristics that currently drives clinical decision making. This review focuses on defining some of the principle components of personalized medicine. In addition we will review the pharmacological and pharmacogenetic predictors of toxic effects of chemotherapeutic agents drawing on examples of commonly used agents in oncology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479485     DOI: 10.1080/07357900802574660

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  10 in total

1.  Biomarker discovery and clinical proteomics.

Authors:  Jerzy Silberring; Pawel Ciborowski
Journal:  Trends Analyt Chem       Date:  2010-02-01       Impact factor: 12.296

2.  Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions.

Authors:  Casey Lynnette Overby; Emily Beth Devine; Peter Tarczy-Hornoch; Ira J Kalet
Journal:  J Am Med Inform Assoc       Date:  2012-04-26       Impact factor: 4.497

3.  Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type.

Authors:  Ana Jorge-Finnigan; Sandra Brasil; Jarl Underhaug; Pedro Ruíz-Sala; Begoña Merinero; Ruma Banerjee; Lourdes R Desviat; Magdalena Ugarte; Aurora Martinez; Belén Pérez
Journal:  Hum Mol Genet       Date:  2013-05-13       Impact factor: 6.150

4.  Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.

Authors:  Sergio Crovella; Lara Biller; Sergio Santos; Ana Salustiano; Lucas Brandao; Rafael Guimaraes; Ludovica Segat; Jose Luiz de Lima Filho; Luiz Claudio Arraes
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 5.  Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges.

Authors:  Vivek P Chavda; Aayushi B Patel; Kavya J Mistry; Suresh F Suthar; Zhuo-Xun Wu; Zhe-Sheng Chen; Kaijian Hou
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

6.  Selective cell cycle arrest and induction of apoptosis in human prostate cancer cells by a polyphenol-rich extract of Solanum nigrum.

Authors:  Akbar Nawab; Vijay S Thakur; Mohammad Yunus; Abbas Ali Mahdi; Sanjay Gupta
Journal:  Int J Mol Med       Date:  2011-11-10       Impact factor: 4.101

7.  Effect of chemotherapy on effect-site concentration of propofol for loss of consciousness in patients with colorectal cancer.

Authors:  Seunghee Ki; Yongwon Cho; Youngkyung Choi; Sehun Lim; Myounghun Kim; Jeonghan Lee
Journal:  Korean J Anesthesiol       Date:  2021-09-17

Review 8.  Advanced Cellular Models for Preclinical Drug Testing: From 2D Cultures to Organ-on-a-Chip Technology.

Authors:  Valentina Foglizzo; Emiliano Cocco; Serena Marchiò
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

9.  Prediction of clinical toxicity in locally advanced head and neck cancer patients by radio-induced apoptosis in peripheral blood lymphocytes (PBLs).

Authors:  Elisa Bordón; Luis Alberto Henríquez-Hernández; Pedro C Lara; Ana Ruíz; Beatriz Pinar; Carlos Rodríguez-Gallego; Marta Lloret
Journal:  Radiat Oncol       Date:  2010-01-28       Impact factor: 3.481

10.  Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.

Authors:  Lihui Wang; Guoliang Chen; Kang Chen; Yong Ren; Huahuan Li; Xiaorui Jiang; Lina Jia; Shiyuan Fu; Yi Li; Xinwei Liu; Shuang Wang; Jingyu Yang; Chunfu Wu
Journal:  Oncotarget       Date:  2015
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.